Lactose India Ltd
- Market cap
- ₹ 125 Cr.
- P/E
- 19.4x
- P/B
- 1.93x
- 52-week range
- 76.01 – 136.45
- ROE
- 10%
- ROCE
- 11%
- Dividend yield
- 0%
- Debt / equity
- 0.97
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Lactose (India) Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing, trading and carrying out job work and manufacturing of pharmaceutical products. The Company specializes in the manufacturing of excipients (lactose/liquid color coatings), lactulose, solid dosage forms and liquid dosage forms. It specializes in manufacturing of lactose monohydrate IP/BP/EP/USP-NF grades. The Company’s lactose products include Formulac 200M, Formulac 80M, Formulac 100M, Formulac 325M, Formulac DC60, Formulac 450M, Formulac 314M and Formulac DC2050. It is also engaged in the manufacturing of disaccharide lactulose, a versatile bulk API. Disaccharide Lactulose (galacto-fructose) is synthesized from lactose (galacto-glucose) by isomerization of glucose to fructose. Lactulose is used in the treatment of constipation, hepatitis, encephalopathy, intestinal microflora, dental care, diabetes, chronic liver disease and as an effective prebiotic.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Lactose India Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)19.4 against a typical 34.6: cheaper than most peers (1st = cheapest).54th of 220
- Sales growth+18.7% against a typical +15.6% from a year earlier.87th of 197
- Profit growth+58% against a typical +18.9% from a year earlier.46th of 160
- Share price, 3 months+1.8% against a typical −0.5%.89th of 200
- Size₹ 125.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).140th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 33 | 29 | 29 | 30 | 29 | 28 | 40 | 41 | 37 | 46 | 47 |
| Expenses | 21 | 27 | 23 | 24 | 25 | 26 | 24 | 35 | 36 | 34 | 41 | 41 |
| Operating Profit | 3 | 6 | 6 | 6 | 5 | 3 | 3 | 4 | 5 | 3 | 5 | 6 |
| OPM % | 13.9% | 17.6% | 20.8% | 18.9% | 16.5% | 10.3% | 12.3% | 11.3% | 12.8% | 8.3% | 11% | 12.9% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 1 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 3 | 1 | 2 | 3 |
| Tax % | 29% | 27% | 33.9% | 29.7% | 22.2% | 59.3% | −18.2% | 34.5% | 31.1% | 40.2% | 18.6% | 26.9% |
| Net Profit | 1 | 3 | 2 | 2 | 2 | 0 | 1 | 2 | 2 | 1 | 2 | 2 |
| EPS in Rs | 0.64 | 2.09 | 1.91 | 1.8 | 1.61 | 0.17 | 0.51 | 1.19 | 1.72 | 0.42 | 1.49 | 1.88 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 17%
- 5 Years
- 36%
- 3 Years
- 35%
- TTM
- 35%
- 10 Years
- 10%
- 5 Years
- 35%
- 3 Years
- 72%
- TTM
- 58%
- 10 Years
- 3%
- 5 Years
- 23%
- 3 Years
- 16%
- TTM
- —
- 10 Years
- 5%
- 5 Years
- 9%
- 3 Years
- 11%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Lactose India Ltd | ₹ 107.00 | ₹ 125 Cr. | 19.4x | 1.9x | 10% | — |
| Nestle India | ₹ 1,173.45 | ₹ 2,26,278 Cr. | 80.4x | 53.4x | 76.3% | 15.1% |
| Britannia Industries | ₹ 4,547.80 | ₹ 1,09,542 Cr. | 51.5x | 25.5x | 53.6% | 13.3% |
| Tata Consumer Products | ₹ 960.00 | ₹ 95,010 Cr. | 67.4x | 4.9x | 7.4% | 8.1% |
| Godrej Industries | ₹ 918.00 | ₹ 30,884 Cr. | 34.9x | 4x | 11.6% | 10.9% |
| Patanjali Foods | ₹ 351.00 | ₹ 38,193 Cr. | 18.9x | 2.8x | 14.8% | 4.5% |
Management
- S. M. Maheshwari
- Executive Chairman of the Board, Managing Director
- Ritesh Kumar Pandey
- Compliance Officer, Company Secretary
- Atul Maheshwari
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.